Thomas Aparicio

Centre National de la Recherche Scientifique

Also affiliated with Inserm, Université Paris Cité, Université de Lille, Centre Hospitalier Universitaire de Lille, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 4 papers. Top paper: “Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer”.

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

JAMA Oncology(2022)10.1001/jamaoncol.2022.3829

N/A

9.5DataRank · unranked

335 citations

Florence Castan, Anthony Lopez, Anthony Turpin, Meher Ben Abdelghani, Alice C. Wei +87 more

FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).

Journal of Clinical Oncology(2018)10.1200/jco.2018.36.15_suppl.4000

N/A

0.601DataRank · unranked

54 citations

Jean Marc Phelip, Karine Le Malicot, Nicolas Williet, Jérôme Desrame, Julien Volet +13 more

Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis

The Lancet Oncology(2022)10.1016/s1470-2045(22)00506-x

N/A

0DataRank · unranked

65 citations

Jasme Lee, Lily V. Saadat, Thomas Aparicio, Florian E. Buisman, Vinod P. Balachandran +15 more

LBA54 Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according to the O6-methylguanine-DNA methyltransferase (MGMT) status: A randomized phase II study (MGMT-NET) on behalf of the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN network

Annals of Oncology(2023)10.1016/j.annonc.2023.10.048

N/A

0DataRank · unranked

7 citations

Thierry Lecomte, Julien Hadoux, Patricia Niccoli, Léa Saban-Roche, E. Gaye +15 more